|
See related Sutent cap information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Zuellig |
|
Contents |
Sunitinib malate |
|
Indications |
Treatment of GI stromal tumor (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance & metastatic renal cell carcinoma (MRCC).
Click to view Sutent detailed prescribing infomation |
|
Dosage |
50 mg/day for 4 consecutive wk, followed by a 2-wk rest period (schedule 4/2) to complete a 6-wk cycle.
Click to view Sutent detailed prescribing infomation |
|
Overdosage |
View Sutent overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
[Click for Sutent detailed prescribing infomation] |
|
Special Precautions |
Perform complete blood count & physical exam, liver & renal function assessment. Concomitant treatment w/ potent CYP3A4 inhibitors & inducers. Risk of osteonecrosis of the jaw (ONJ) when given w/ IV bisphosphonates. Avoid invasive dental procedures. Impaired liver & hepatic function. Childn. Pregnancy & lactation.
Click to view Sutent detailed prescribing infomation |
|
Adverse Drug Reactions |
Pulmonary embolism, thrombocytopenia, tumor hemorrhage, febrile neutropenia, HTN, fatigue, GI disorders, skin discoloration, dysgeusia, anorexia, increased lipase, ONJ. Hypothyroidism, QT prolongation, HFS, decrease LVEF, pancreatic function.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin). CYP3A4 inducers (rifampicin, dexamethasone, phenytoin, carbamazepine, phenobarb, St. John's wort).
View more drug interactions with Sutent |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Description |
View Sutent description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Sutent mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Sutent capsule |
|
Sutent 12.5 mg x 28's |
 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Zuellig
|
|
|
|
